SES
EAGLE-1 consortium lead SES announces a new key partner, TESAT, responsible for developing and integrating the Quantum Key Distribution (QKD) payload for the EAGLE-1 satellite. The SES and TESAT partnership is aimed at achieving the next key milestone in building and implementing Europe’s pioneering quantum secure communications initiative EAGLE-1. Supported by the European Space Agency (ESA) and the European Commission, EAGLE-1 is a quantum key system integrating both space and ground segments that will deliver secure transmission of encryption keys across geographically dispersed areas and connect EU’s national quantum communications infrastructures for truly sovereign networks.
Consortium member and Europe’s leading laser communication technology company TESAT will manufacture the QKD payload comprising the Scalable Optical Terminal SCOT80 to establish a secure optical link from space to ground, as well as the QKD module of the satellite.
The technology integrated into the EAGLE-1 system’s payload will include built-in redundancy and is specifically designed to be associated with the satellite communications and data transmission for such areas as government, telco operators, cloud providers and banking, to add guaranteed security of the cryptographic applications.
“EAGLE-1 is a project that will benefit the whole of Europe, and being able to work with the leading technology players in the market to co-develop it and together shape this innovative secure technology is a privilege to SES,” said Ruy Pinto, Chief technology Officer of SES. “The addition of the secure optical links and the actual QKD module brings us closer to implementation, testing and further scaling the technology, that can ultimately serve millions of users. This elevates secure communications to an entirely new level, supporting development of reliable pan-European quantum communications infrastructures.”
“We are delighted to be selected as payload prime by SES and looking forward to bring our expertise in integrating secure technologies, and a track record of almost 80,000 executed optical satellite links for the benefit of this highly-important and timely European project,” said Thomas Reinartz, CEO of TESAT. “The EAGLE-1 system allows for achieving synergies together with leading industry partners, SMEs and institutes, reducing time to service and to market for the quantum secure technologies and its future key users, such as governments and institutions, or banking sector. Together with our partners, we are looking forward to strengthen European collaboration at all levels, including SMEs and institutions and contributing to European sovereignty in space.”
About EAGLE-1
The EAGLE-1 project comprising satellite and ground infrastructure is developed by SES and its consortium of 20 European partners, and is co-funded by the ESA contribution of Germany, Luxembourg, Austria, Italy, the Netherlands, Switzerland, Belgium, and the Czech Republic under ARTES, as well as the European Commission through Horizon Europe.
Once launched in 2024, the EAGLE-1 satellite will complete three years of in-orbit mission. During the operational phase, the satellite will allow European Union governments and institutions as well as critical business sectors early access to long-distance QKD that would path the way towards an EU constellation enabling ultra-secure data transmissions.
Learn more about EAGLE-1 and SES-led consortium of European partners here.
Follow us on:
Twitter | Facebook | YouTube | LinkedIn | Instagram
Read our Blogs >
Visit the Media Gallery >
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over ~8,200 channels and has an unparalleled reach of 369 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com
About TESAT
TESAT is a world-leading manufacturer for satellite equipment. More than 1,100 employees, based in Backnang, Germany, develop, manufacture and distribute systems and equipment for satellite communications every day. The product range spans from the smallest space-specific components to modules, entire assemblies or payloads. As the world’s leading provider of in-orbit-verified optical communication terminals for data transmission via laser, TESAT has a focus on commercial and institutional space programs. Thanks to the deep understanding of the market needs, customer focus and technological innovation, TESAT offers products that contribute to sustainable development and security, for the people, for a better world. More information at www.tesat.de.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230510006052/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom